The Science and Ethics of Antipsychotic Use in Children reviews the latest findings for the safety and efficacy of the rapidly rising incidence of antipsychotic use in children and examines tensions that are created by off-label use, both in clinical psychiatric practice and research. In the past ten years, the number of antipsychotics prescribed to children with psychiatric disorders has skyrocketed. Despite this rapid growth, most medications have been inadequately studied in children for safety or efficacy and many have serious adverse health. Measures are needed to ensure that the health and safety of children are being protected, and debates have emerged over whether or not clinical trials in this population should be conducted.
- Offers coverage of efficacy, prevalence, and adverse impacts of the use of antipsychotics in children
- Explores ethics challenges of clinical research in this patient population
- Serves as a platform for future discussions designed to increase the safety of children taking antipsychotics
- Edited work with chapters authored by leading neuroethicists in the field around the globe - the broadest, most expert coverage available
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
1: A Brief History of the Science and Ethics of Antipsychotics and Off-label Prescribing 2: Pharmacoepidemiology of antipsychotic use in Canadian children and adolescents 3: Do We Know if they Work and if they are Safe: Second Generation Antipsychotics for treatment of Autism Spectrum Disorders and Disruptive Behavior Disorders in Children and Adolescents. 4: Ensuring the safety of children treated with second-generation antipsychotics 5: Pediatric clinical trial activity for antipsychotics and the sharing of results
a complex ethical landscape 6: Pathways to Overmedication and Polypharmacy: Case Examples from Adolescents with Fetal Alcohol Spectrum Disorders 7: Implementing Change in Prescribing Practices 8: Canadian initiatives and recommendations: Safeguarding the health of children and youth receiving off-label treatment with antipsychotics
Senior Research Fellow at the University of British Columbia's "National Core for Neuroethics, Dr. Di Pietro also serves as the Neuroethics Program Lead for NeuroDevNet (Canadian org focused on children's neurodevelopmental disorders) and is described by one reviewer as "a rising force in the field of neuroethics and developmental neuroscience.
Professor in the Department of Neurology and Research Chair in Neuroethics for the University of British Columbia, Dr. Illes is also Co-founder and Executive Committee Member for the Neuroethics Society. She is one of the leading voices in neuroethics today and has published extensively in this realm (Editor: Handbook of Neuroethics/2011, Neuroethics: Defining the Issues in Theory, Practice, and Policy/2005). She also serves as Chair for the International Brain Research Organization (IBRO), Committee Chair for Society for Neuroscience, Editorial Board Member for Journal of Ethics in Mental Health, and Senior Editorial Advisor for American Journal of Bioethics: Neuroscience.